美国队列中产后药物性血栓预防与并发症
该研究为美国17家医院多中心队列的二次分析,纳入2019-2020年随机日期分娩者21114例,其中11.9%接受产后药物性血栓预防,剖宫产后为29.8%、阴道分娩后为3.5%,各机构率0.21%-34.8%;剖宫产、子宫切除和肥胖是与预防用药最强相关的因素,预防用药与手术部位感染、出血并发症或产后再入院无显著关联。
要点
- 产后药物性血栓预防总体率为11.9%,剖宫产后29.8%,阴道分娩后3.5%。
- 各机构预防率差异大,范围0.21%至34.8%。
- 剖宫产、子宫切除和肥胖是与预防用药最强相关的因素。
核心结论
- 在该美国队列中约十分之一患者接受了产后药物性血栓预防,各机构预防率差异很大,剖宫产、子宫切除和肥胖是与产后血栓预防用药相关的主要因素。
研究设计与样本
- 研究为美国17家医院多中心队列的二次分析,纳入2019-2020年随机选定日期分娩者,排除产前诊断静脉血栓栓塞症、产前接受抗凝或已知SARS-CoV-2感染者,最终分析队列21114例。
主要发现
- 21114例中11.9%(95%CI 11.4%-12.3%)接受产后药物性血栓预防,剖宫产后为29.8%(95%CI 28.7%-30.9%),阴道分娩后为3.5%(95%CI 3.2%-3.8%)。
- 各机构预防率范围为0.21%至34.8%,83.3%的个体仅在住院期间接受血栓预防。
- 调整分析中,剖宫产(aOR 19.17,95%CI 16.70-22.00)、子宫切除(aOR 15.70,95%CI 4.35-56.65)和肥胖(aOR 3.45,95%CI 3.02-3.95)是与血栓预防用药最强相关的因素。
- 血栓预防用药与手术部位感染(0.9% vs 0.6%;OR 1.48,95%CI 0.80-2.74)、出血并发症(0.2% vs 0.1%;OR 2.60,95%CI 0.99-6.80)或产后再入院(0.9% vs 0.3%;aOR 1.38,95%CI 0.68-2.81)无显著关联。
- 总体静脉血栓栓塞症发生率为0.06%(95%CI 0.03%-0.10%),接受预防者中为0.2%,未接受预防者中为0.04%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Venous thromboembolism accounts for approximately 9% of pregnancy-related deaths in the United States. National guidelines recommend postpartum risk stratification and pharmacologic prophylaxis in at-risk individuals. Knowledge on modern rates of postpartum pharmacologic thromboprophylaxis and its associated risks is limited. OBJECTIVE: This study aimed to describe the rate of, and factors associated with, initiation of postpartum pharmacologic prophylaxis for venous thromboembolism, and to assess associated adverse outcomes. STUDY DESIGN: This was a secondary analysis of a multicenter cohort of individuals delivering on randomly selected days at 17 US hospitals (2019-2020). Medical records were reviewed by trained and certified personnel. Those with an antepartum diagnosis of venous thromboembolism, receiving antepartum anticoagulation, or known SARS-CoV-2 infection were excluded. The primary outcome was use of postpartum pharmacologic thromboprophylaxis. Secondary outcomes included bleeding complications, surgical site infection, hospital readmission, and venous thromboembolism through 6 weeks postpartum. The rate of thromboprophylaxis administration was assessed by mode of delivery, institution, and continuance to the outpatient setting. Multivariable regression models were developed using k-fold cross-validation with stepwise backward elimination to evaluate factors associated with thromboprophylaxis administration. Univariable and multivariable logistic models with propensity score covariate adjustment were performed to assess the association between thromboprophylaxis administration and adverse outcomes. RESULTS: Of 21,114 individuals in the analytical cohort, 11.9% (95% confidence interval, 11.4%-12.3%) received postpartum pharmacologic thromboprophylaxis; the frequency of receipt was 29.8% (95% confidence interval, 28.7%-30.9%) following cesarean and 3.5% (95% confidence interval, 3.2%-3.8%) following vaginal delivery. Institutional rates of prophylaxis varied from 0.21% to 34.8%. Most individuals (83.3%) received thromboprophylaxis only as inpatients. In adjusted analysis, cesarean delivery (adjusted odds ratio, 19.17; 95% confidence interval, 16.70-22.00), hysterectomy (adjusted odds ratio, 15.70; 95% confidence interval, 4.35-56.65), and obesity (adjusted odds ratio, 3.45; 95% confidence interval, 3.02-3.95) were the strongest factors associated with thromboprophylaxis administration. Thromboprophylaxis administration was not associated with surgical site infection (0.9% vs 0.6%; odds ratio, 1.48; 95% confidence interval, 0.80-2.74), bleeding complications (0.2% vs 0.1%; odds ratio, 2.60; 95% confidence interval, 0.99-6.80), or postpartum readmission (0.9% vs 0.3%; adjusted odds ratio, 1.38; 95% confidence interval, 0.68-2.81). The overall rate of venous thromboembolism was 0.06% (95% confidence interval, 0.03%-0.10%) and was higher in those receiving prophylaxis (0.2%) compared with those not receiving prophylaxis (0.04%). CONCLUSION: Approximately 1 in 10 patients received postpartum pharmacologic thromboprophylaxis in this US cohort. Rates of prophylaxis varied widely by institution. Cesarean delivery, hysterectomy, and obesity were predominant factors associated with postpartum thromboprophylaxis administration.
引用
- Bruno AM, Sandoval GJ, Hughes BL, et al. Postpartum pharmacologic thromboprophylaxis and complications in a US cohort. Am J Obstet Gynecol. 2024. PMID: 38346912. doi:10.1016/j.ajog.2023.11.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。